Literature DB >> 11815289

Peribiliary myofibroblasts in biliary type liver fibrosis.

Nils Kinnman1, Chantal Housset.   

Abstract

Biliary type liver fibrosis develops as part of the wound healing response to bile duct injury in chronic cholestatic liver diseases. The origin of myofibroblasts accumulating together with extracellular matrix around proliferating bile duct structures (referred to as ductular reaction) in the setting of cholestatic injury, has been investigated mostly in the rat bile duct ligation model. Evidence indicates that hepatic stellate cells undergo a myofibroblastic transition following bile duct ligation and that myofibroblastic hepatic stellate cells disclose chemoattraction towards bile duct structures in cholestatic liver. On the basis of morphological studies, nevertheless, the origin of peribiliary myofibroblasts has also been attributed to the activation and proliferation of portal fibroblasts. Bile duct epithelial cells of the ductular reaction actively contribute to the promotion and regulation of biliary type liver fibrogenesis. They synthesize and release a number of paracrine mediators such as transforming growth factor-beta, connective tissue growth factor, platelet-derived growth factor-BB, and endothelin-1 that target different liver cell types, including hepatic stellate cells and portal fibroblasts. Through these interactions, bile duct epithelial cells and peribiliary myofibroblasts cause periportal fibrosis in cholestatic and also probably other types of liver diseases.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11815289     DOI: 10.2741/A790

Source DB:  PubMed          Journal:  Front Biosci        ISSN: 1093-4715


  36 in total

Review 1.  Idiopathic pulmonary fibrosis: pathogenesis and therapeutic approaches.

Authors:  Moisés Selman; Victor J Thannickal; Annie Pardo; David A Zisman; Fernando J Martinez; Joseph P Lynch
Journal:  Drugs       Date:  2004       Impact factor: 9.546

2.  Contribution of Myofibroblasts of Different Origins to Liver Fibrosis.

Authors:  Michel Fausther; Elise G Lavoie; Jonathan A Dranoff
Journal:  Curr Pathobiol Rep       Date:  2013-09

Review 3.  Mechanisms of hepatic fibrogenesis.

Authors:  Ursula E Lee; Scott L Friedman
Journal:  Best Pract Res Clin Gastroenterol       Date:  2011-04       Impact factor: 3.043

4.  Magnetic resonance-based total liver volume and magnetic resonance-diffusion weighted imaging for staging liver fibrosis in mini-pigs.

Authors:  Hang Li; Tian-Wu Chen; Xiao-Li Chen; Xiao-Ming Zhang; Zhen-Lin Li; Nan-Lin Zeng; Li Zhou; Li-Ying Wang; Hong-Jie Tang; Chun-Ping Li; Li Li; Xian-Yong Xie
Journal:  World J Gastroenterol       Date:  2012-12-28       Impact factor: 5.742

Review 5.  Hepatosplanchnic circulation in cirrhosis and sepsis.

Authors:  Meghan Prin; Jan Bakker; Gebhard Wagener
Journal:  World J Gastroenterol       Date:  2015-03-07       Impact factor: 5.742

6.  Hepatocyte growth factor attenuates liver fibrosis induced by bile duct ligation.

Authors:  Jing-Lin Xia; Chunsun Dai; George K Michalopoulos; Youhua Liu
Journal:  Am J Pathol       Date:  2006-05       Impact factor: 4.307

Review 7.  The portal fibroblast: not just a poor man's stellate cell.

Authors:  Rebecca G Wells
Journal:  Gastroenterology       Date:  2014-05-09       Impact factor: 22.682

Review 8.  Cellular sources of extracellular matrix in hepatic fibrosis.

Authors:  Rebecca G Wells
Journal:  Clin Liver Dis       Date:  2008-11       Impact factor: 6.126

Review 9.  Bioconjugation of oligonucleotides for treating liver fibrosis.

Authors:  Zhaoyang Ye; Houssam S Hajj Houssein; Ram I Mahato
Journal:  Oligonucleotides       Date:  2007

10.  Oxidized low-density-lipoprotein accumulation is associated with liver fibrosis in experimental cholestasis.

Authors:  Güldeniz Karadeniz; Serefden Acikgoz; Ishak Ozel Tekin; Oge Tascýlar; Banu Dogan Gun; Mustafa Cömert
Journal:  Clinics (Sao Paulo)       Date:  2008-08       Impact factor: 2.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.